Lymphomas are a heterogeneous group of lymphoproliferative malignancies with differing patterns of behaviour and responses to treatment. From the 1960's through the early 1990's, a variety of non-Hodgkin's lymphoma (NHL) classifications were used in different parts of the world, most recently the Kiel classification in Europe and the Working Formulation (WF) in the U.S.A. Unfortunately, none of the classification systems used to date has been able to be accurately and reproducibly applied when objective tests were performed. Over the last decade, significant observations regarding the immunology and genetics of lymphomas have allowed identification of previously unrecognized subtypes that were placed throughout different groups of the WF. The recognition of these new entities has led to a new proposal, the Revised European-American Lymphoma (REAL) classification by the International Lymphoma Study Group. Instead of using only morphologic subgroups, all information, including morphology, immunophenotype, genetic abnormalities, and clinical observations, was used to identify specific types of NHL. Recently, the Society of Hematopathology of U.S.A. and the European Association of Hematopathologists jointly developed a classification of hematologic neoplasms for the World Health Organization (WHO). The proposed WHO classification of hematologic malignancies stratifies neoplasms primarily according to their lineage: myeloid neoplasms, lymphoid neoplasms, mast cell disorders and histiocytic neoplasms. Within each category, distinct diseases are defined according to a combination of morphology, immunophenotype, genetic features, and clinical syndromes. The goal was to define disease entities that could be recognized by pathologists and that have clinical relevance.
|Translated title of the contribution||Classification of non-Hodgkin's lymphomas|
|Number of pages||6|
|Journal||Impegno Ospedaliero, Sezione Scientifica|
|Publication status||Published - 2001|
ASJC Scopus subject areas